Citigroup Cuts Biogen Price Target

Biotech firm's stock rating remains neutral despite target reduction

Apr. 13, 2026 at 1:53pm

Got story updates? Submit your updates here. ›

A highly detailed, textured close-up image of complex banking machinery and mechanical components in shades of grey, bronze, and black, conceptually representing the volatility and uncertainty surrounding Biogen's stock price.An extreme close-up of Biogen's financial infrastructure and institutional banking mechanisms reflects the volatility and uncertainty surrounding the biotech firm's stock price.Cambridge Today

Citigroup has lowered its price target for Biogen (NASDAQ:BIIB) from $215.00 to $190.00, while maintaining a 'neutral' rating on the biotechnology company's stock. The new target price still represents a potential upside of 9.47% from the stock's current trading level.

Why it matters

Biogen's stock price has been volatile in recent months as the company navigates a competitive landscape for its multiple sclerosis treatments. Analyst price target adjustments can significantly impact investor sentiment and trading activity around biotech firms like Biogen.

The details

In a research note issued on Monday, Citigroup analysts reduced their price target on Biogen shares, citing ongoing challenges for the company. Several other brokerages have also recently weighed in on Biogen, with Piper Sandler increasing its target to $177.00 and Guggenheim raising its target to $246.00. Overall, the consensus rating on Biogen stock remains 'Hold' among Wall Street analysts.

  • Citigroup issued the updated price target on Biogen on Monday, April 13, 2026.

The players

Citigroup

A major global investment bank and financial services corporation.

Biogen

A multinational biotechnology company focused on developing therapies for neurological and neurodegenerative diseases.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Biogen's upcoming financial results and any further commentary from the company on its product pipeline and competitive positioning.

The takeaway

Biogen's stock price continues to face pressure as the company navigates a challenging environment for its core multiple sclerosis treatments. Analyst price target adjustments reflect the ongoing uncertainty around the biotech firm's long-term growth prospects.